136 related articles for article (PubMed ID: 32941327)
1. Preventing cancer therapy-related heart failure: the need for novel studies.
Fogarassy G; Vathy-Fogarassy Á; Kenessey I; Veress G; Polgár C; Forster T
J Cardiovasc Med (Hagerstown); 2021 Jun; 22(6):459-468. PubMed ID: 32941327
[TBL] [Abstract][Full Text] [Related]
2. Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer - A real-world data-based, nationwide classification analysis.
Fogarassy G; Vathy-Fogarassy Á; Kenessey I; Kásler M; Forster T
Int J Cardiol; 2019 Jun; 285():47-52. PubMed ID: 30905520
[TBL] [Abstract][Full Text] [Related]
3. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study.
Abdel-Qadir H; Bobrowski D; Zhou L; Austin PC; Calvillo-Argüelles O; Amir E; Lee DS; Thavendiranathan P
J Am Heart Assoc; 2021 Jan; 10(2):e018393. PubMed ID: 33401953
[TBL] [Abstract][Full Text] [Related]
4. Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity.
Khan AA; Ashraf A; Singh R; Rahim A; Rostom W; Hussain M; Renner I; Collins NJ
Intern Med J; 2017 Jan; 47(1):104-109. PubMed ID: 27800661
[TBL] [Abstract][Full Text] [Related]
5. [Analysing the risk factors of doxorubicin-associated heart failure by a retrospective study of integrated, nation-wide databases].
Fogarassy G; Fogarassyné Vathy Á; Kováts T; Hornyák L; Kenessey I; Veress G; Polgár C; Forster T
Orv Hetil; 2020 Jun; 161(26):1094-1102. PubMed ID: 32541088
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
Lee J; Lee S
Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
[TBL] [Abstract][Full Text] [Related]
7. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
Blanter JB; Frishman WH
Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
Tang CH; Wang CC; Chen TH; Hong CY; Sue YM
J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26738790
[TBL] [Abstract][Full Text] [Related]
9. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
Bowles EJ; Wellman R; Feigelson HS; Onitilo AA; Freedman AN; Delate T; Allen LA; Nekhlyudov L; Goddard KA; Davis RL; Habel LA; Yood MU; McCarty C; Magid DJ; Wagner EH;
J Natl Cancer Inst; 2012 Sep; 104(17):1293-305. PubMed ID: 22949432
[TBL] [Abstract][Full Text] [Related]
10. Heart failure from cancer therapy: can we prevent it?
Totzeck M; Mincu RI; Heusch G; Rassaf T
ESC Heart Fail; 2019 Aug; 6(4):856-862. PubMed ID: 31297946
[TBL] [Abstract][Full Text] [Related]
11. Prevention of Chemotherapy Induced Cardiomyopathy.
Payne DL; Nohria A
Curr Heart Fail Rep; 2017 Oct; 14(5):398-403. PubMed ID: 28779279
[TBL] [Abstract][Full Text] [Related]
12. The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.
Cavarretta E; Mastroiacovo G; Lupieri A; Frati G; Peruzzi M
Adv Exp Med Biol; 2017; 1000():103-129. PubMed ID: 29098619
[TBL] [Abstract][Full Text] [Related]
13. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
14. Renin-angiotensin system blockade in heart failure patients on long-term haemodialysis in Taiwan.
Tang CH; Chen TH; Wang CC; Hong CY; Huang KC; Sue YM
Eur J Heart Fail; 2013 Oct; 15(10):1194-202. PubMed ID: 23671265
[TBL] [Abstract][Full Text] [Related]
15. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.
Seicean S; Seicean A; Plana JC; Budd GT; Marwick TH
J Am Coll Cardiol; 2012 Dec; 60(23):2384-90. PubMed ID: 23141499
[TBL] [Abstract][Full Text] [Related]
16. National prescribing trends for heart failure medications in children.
Moffett BS; Price JF
Congenit Heart Dis; 2015; 10(1):78-85. PubMed ID: 24725766
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure.
Seicean S; Seicean A; Alan N; Plana JC; Budd GT; Marwick TH
Circ Heart Fail; 2013 May; 6(3):420-6. PubMed ID: 23425978
[TBL] [Abstract][Full Text] [Related]
18. Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.
Castelli G; Fornaro A; Ciaccheri M; Dolara A; Troiani V; Tomberli B; Olivotto I; Gensini GF
Circ Heart Fail; 2013 Sep; 6(5):913-21. PubMed ID: 23888044
[TBL] [Abstract][Full Text] [Related]
19. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
[TBL] [Abstract][Full Text] [Related]
20. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
